Synovial Fibroblast 3.2: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis-diagnosed donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 2 of 2) - Dataset (ID:20235)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 753.0 | 69 | |
N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 977.0 | 76 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 823.0 | 68 | |
RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 982.0 | 65 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 981.5 | 76 | |
N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 1060.0 | 59 | |
RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 1343.5 | 72 | |
RA1869 | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 1582.5 | 66 | ||||
N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 1809.5 | 54 | |
N2759 | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 1824.0 | 69 | ||||
RA1931 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 2165.0 | 59 | |
RA1931 | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 1772.0 | 65 | ||||
N2586 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 1856.5 | 66 | |
N2586 | IL-1 alpha | 100 | ng/mL | 3 | VEGF | 1745.5 | 64 | ||||
RA1869 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | VEGF | 631.0 | 75 | |
RA1869 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | VEGF | 799.0 | 79 | |
N2759 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | VEGF | 835.0 | 61 | |
N2759 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | VEGF | 1196.0 | 73 | |
RA1931 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | VEGF | 1154.0 | 79 | |
RA1931 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | VEGF | 1234.5 | 82 | |
N2586 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 3 | VEGF | 1122.0 | 64 | |
N2586 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 3 | VEGF | 1380.0 | 63 | |
RA1869 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | VEGF | 1445.0 | 60 | |
RA1869 | TNF-a | 100 | ng/mL | 3 | VEGF | 1218.0 | 65 | ||||
N2759 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 3 | VEGF | 1219.5 | 76 |